Virusight Diagnostic

Company Overview

Snapshot

Founded in October 2020, Virusight Diagnostic operates with 1-10 employees. In October 2020, the company achieved a significant milestone with its Pathogens Diagnostic device demonstrating 96.3% accuracy in detecting COVID-19, comparable to RT-PCR tests, and securing IVD approval in Europe.

Business overview

Virusight Diagnostic is an AI software company focused on pathogen diagnosis using spectral acquisition and analysis technology. Born from a collaboration between Newsight Imaging and Sheba Hospital, the company's core product utilizes AI modules to analyze spectral signatures of pathogens obtained by Newsight's SpectraLI spectrometer device. This solution enables rapid detection of viral infections from a subject's reaction, serving the healthcare and life sciences industries, particularly in digital medical diagnostics and medical devices.

Strategic signal

In May 2022, Virusight Diagnostic announced that its Pathogens Diagnostic device demonstrated 96.3% accuracy in detecting COVID-19, rivaling the RT-PCR test, following a study with TechnoGenetics SpA. This signals strong validation of its AI and spectral technology, positioning the company for significant market penetration in diagnostic testing, especially with its IVD approval in Europe and pending regulatory approvals in other key markets.

Company Intelligence Q&A

What is Virusight Diagnostic's core technology for pathogen detection?

Virusight Diagnostic utilizes AI software combined with spectral acquisition and analysis technology. Its solution employs AI modules to interpret spectral signatures of pathogens, obtained via Newsight's SpectraLI spectrometer device, to determine the presence of infection.

What was a key development regarding Virusight Diagnostic's COVID-19 testing capabilities in May 2022?

In May 2022, Virusight Diagnostic announced that its Pathogens Diagnostic device achieved 96.3% accuracy in detecting COVID-19, comparable to the RT-PCR test. This was based on a study conducted by researchers from the University of Sannio, Italy, in collaboration with partner company TechnoGenetics SpA.

Has Virusight Diagnostic received any regulatory approvals for its diagnostic device?

Yes, the Pathogens Diagnostic device is approved as an in vitro diagnostic (IVD) device in Europe. As of May 2022, it was awaiting regulatory approval in the US, UK, Latin America, and Asia Pacific.

What was the significance of the European approval for Newsight's rapid coronavirus test in March 2021?

In March 2021, Newsight, a collaborator with Virusight Diagnostic, received European approval for its rapid coronavirus test using the handheld SpectraLIT machine. This approval was expected to facilitate the rollout of the test across the European Union, including at airports, and highlighted the technology's potential for detecting other pathogens.

What was the outcome of the initial clinical trial for the super-quick saliva test for COVID-19 at Sheba Medical Center in August 2020?

In August 2020, Sheba Medical Center, a partner in the development of Virusight Diagnostic, trialed a saliva test for COVID-19 that could determine infection in less than a second. The initial clinical trial showed the device identified the virus with a 95% success rate. Sheba Medical Center partnered with Newsight Imaging to bring this system to market.